CoChat

Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial

Open access
Caliman-Fontesa, Ana Teresa, Leal, Gustavo C., Correia-Melo, Fernanda S., Paixão, Camilla S., Carvalho, Michelle S., Jesus-Nunes, Ana Paula, Vieira, Flavia, Magnavita, Guilherme, Bandeira, Igor D., Mello, Rodrigo P., Beanes, Graziele, Silva, Samantha S., Echegaray, Mariana, Carvalho, Lucas P., Machado, Paulo, Sampaio, Aline S., Cardoso, Taiane de A., Kapczinski, Flávio, Lacerda, Acioly L. T., Quarantini, Lucas C. · 2023 · Trends in Psychiatry and Psychotherapy
Cited by 14

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: Evidence suggests that ketamine's influence on brain-derived neurotrophic factor (BDNF) might be involved in its mechanism of rapid antidepressant action. We aimed to evaluate the differential impact of ketamine and esketamine on serum BDNF levels and its association with response patterns in treatment-resistant depression (TRD). METHODS: Participants (n = 53) are from a randomized, double-blind clinical trial comparing the efficacy of single-dose ketamine (0.5mg/kg, n = 27) and esketamine (0.25mg/kg, n = 26) in TRD. Depression severity was assessed before and 24 hours, 72 hours, and 7 days after the intervention, using the Montgomery-Åsberg Depression Rating Scale (MADRS). Blood samples were collected before infusion, 24 hours, and 7 days afterwards. RESULTS: There were no significant changes in BDNF levels at post-infusion evaluation points, and no difference in BDNF levels comparing ketamine and esketamine. Both drugs exhibited similar therapeutic effect. There was no association between BDNF levels and response to treatment or severity of depressive symptoms. CONCLUSION: There was no significant treatment impact on BDNF serum levels - neither with ketamine nor esketamine - despite therapeutic response. These results suggest that ketamine or esketamine intervention for TRD has no impact on BDNF levels measured at 24 hours and 7 days after the infusion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.47626/2237-6089-2021-0298

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 14

Metadata

Authors
Caliman-Fontesa, A. T., Leal, G. C., Correia-Melo, F. S., Paixão, C. S., Carvalho, M. S., Jesus-Nunes, A. P., Vieira, F., Magnavita, G., Bandeira, I. D., Mello, R. P., Beanes, G., Silva, S. S., Echegaray, M., Carvalho, L. P., Machado, P., Sampaio, A. S., Cardoso, T. D. A., Kapczinski, F., Lacerda, A. L. T., & Quarantini, L. C.
Venue
Trends in Psychiatry and Psychotherapy
Published
2023
Volume
45
Pages
e20210298-e20210298
ISSN
  • 2237-6089 (ISSN-L)
  • 2238-0019
OpenAlex
W3202111075
Cited by
14
References
20
FWCI
1.18
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial. https://app.cochat.ai/papers/10.47626/2237-6089-2021-0298
The paper
Caliman-Fontesa, A. T., Leal, G. C., Correia-Melo, F. S., Paixão, C. S., Carvalho, M. S., Jesus-Nunes, A. P., Vieira, F., Magnavita, G., Bandeira, I. D., Mello, R. P., Beanes, G., Silva, S. S., Echegaray, M., Carvalho, L. P., Machado, P., Sampaio, A. S., Cardoso, T. D. A., Kapczinski, F., Lacerda, A. L. T., & Quarantini, L. C. (2023). Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial. Trends in Psychiatry and Psychotherapy. https://doi.org/10.47626/2237-6089-2021-0298

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.